文献速递系统性红斑狼疮

系统性红斑狼疮疾病活动度评分(SLE-DAS)在巴西系统性红斑狼疮患者中的验证

Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该横断面、重测信度、多中心研究纳入365例符合系统性红斑狼疮(SLE)分类标准的成人患者,评估巴西葡萄牙语版SLE-DAS(SLE-DAS Pt-BR)的测量性能。结果显示其组内与组间信度优良(ICC2.1分别为0.999和0.945),与SLEDAI-2K和PGA强相关,对缓解及中重度活动的敏感度、特异度和准确度均高于90%。

要点

  • SLE-DAS Pt-BR与SLEDAI-2K(rho=0.895)及PGA(rho=0.861)强相关。
  • 对缓解和中重度活动的敏感度、特异度及准确度均高于90%,轻度活动高于80%。
  • 按SLEDAI-2K判为缓解者中99.5%经SLE-DAS Pt-BR亦判为缓解。

核心结论

  • SLE-DAS Pt-BR有效且能够测量SLE疾病活动度。

研究设计与样本

  • 横断面、重测信度、多中心研究,纳入365例年龄≥18岁且符合SLE分类标准的患者。
  • 采用类型2.1组内相关系数(ICC2.1)、标准测量误差(SEM)和最小可检测差异(MDD)检验信度。

主要发现

  • 纳入365例患者,平均年龄44.5岁(SD 14.0),女性占92.9%;57.3%按SLE-DAS Pt-BR处于缓解。
  • 组内和组间信度优良,ICC2.1分别为0.999和0.945,SEM/MDD可接受。
  • SLE-DAS Pt-BR与SLEDAI-2K(rho=0.895)和PGA(rho=0.861)强相关。
  • SLE-DAS Pt-BR对缓解和中重度活动的敏感度、特异度及准确度均高于90%,对轻度活动均高于80%。
  • 按SLEDAI-2K判为缓解和中重度活动者中,分别有99.5%和77.9%经SLE-DAS Pt-BR归入相同类别;轻度活动一致性见于42.9%患者。

关键数值与推荐

  • SLE-DAS Pt-BR组内信度ICC2.1=0.999,组间信度ICC2.1=0.945。
  • 与SLEDAI-2K的Spearman相关系数rho=0.895,与PGA的rho=0.861。
  • 对缓解和中重度活动的敏感度、特异度及准确度均高于90%,对轻度活动均高于80%。
  • SLEDAI-2K缓解者中99.5%经SLE-DAS Pt-BR亦为缓解,中重度活动者中77.9%经SLE-DAS Pt-BR亦为中重度活动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the measurement properties of SLE-DAS, using the Brazilian-Portuguese version (SLE-DAS Pt-BR). METHODS: Cross-sectional, test-retest, multicentre study, that included patients ≥18 years old who met the classification criteria for SLE. Reliability was tested using type 2.1 intraclass correlation coefficient (ICC2.1), standard measurement error (SEM) and minimum detectable difference (MDD). For construct validity, Spearman correlation (rho) and/or percentage of agreement with χ2 test were used to correlate/associate SLE-DAS Pt-BR with SLEDAI-2K, PGA and the definitions of remission (DORIS) and low disease activity (LLDAS). Performance of SLE-DAS was assessed with PGA as reference standard, calculating sensitivity, specificity and accuracy. RESULTS: A total of 365 patients were included: mean age 44.5 (SD 14.0) years, 92.9% female. 57.3% were in remission according to SLE-DAS Pt-BR. Excellent intra and inter-rater reliability was observed (ICC2.1 = 0.999 and 0.945, respectively), with acceptable SEM/MDD. There was a strong correlation between SLE-DAS Pt-BR with SLEDAI-2K (rho = 0.895) and PGA (rho = 0.861). Sensitivity, specificity and accuracy of SLE-DAS Pt-BR were above 90% for remission and moderate/severe disease activity and above 80% for mild activity. Most individuals in remission and in moderate/severe activity according to SLEDAI-2K were also in those categories according to SLE-DAS Pt-BR (99.5% and 77.9%, respectively). Considering mild activity concordance was observed in 42.9% patients. Most patients considered in DORIS remission and LLDAS were also in remission and in low disease activity by SLE-DAS Pt-BR. CONCLUSION: The present study demonstrated that the SLE-DAS Pt-BR is valid and capable of measuring SLE disease activity.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mata-Machado CM, Lanna CCD, Garrido JC, et al. Validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Brazilian SLE patients. Rheumatology (Oxford). 2025. PMID: 40613693. doi:10.1093/rheumatology/keaf366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。